Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study
Sign Up to like & getrecommendations! Published in 2019 at "OncoTargets and therapy"
DOI: 10.2147/ott.s193801
Abstract: Purpose The aim of this study was to assess the efficacy and safety of concurrent apatinib and docetaxel therapy vs apatinib monotherapy as third- or subsequent-line treatment for advanced gastric adenocarcinoma (GAC). Methods Patients, who… read more here.
Keywords: apatinib docetaxel; concurrent apatinib; therapy; apatinib monotherapy ... See more keywords
Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review
Sign Up to like & getrecommendations! Published in 2019 at "OncoTargets and therapy"
DOI: 10.2147/ott.s198946
Abstract: Abstract Ovarian cancer is the deadliest gynecologic malignancy, which poses a great threat to female health. Anti-angiogenic therapy could bring clinical benefit for patients with ovarian cancer. Apatinib, an oral small-molecule vascular endothelial growth factor… read more here.
Keywords: apatinib monotherapy; review; ovarian cancer; free survival ... See more keywords
Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1031787
Abstract: Background Osteosarcoma commonly develops during childhood and adolescence. Only one-third of osteosarcoma patients have been clinically detected over the age of 40 years, and the survivorship of those patients is quite dismal. Apatinib, a novel… read more here.
Keywords: apatinib; monotherapy; combined chemotherapy; apatinib monotherapy ... See more keywords